AstraZeneca PLC
AstraZeneca PLC (AZN) has entered a three‑year licensing agreement with AI‑driven drug‑discovery platform Owkin. The deal, announced on 13 May 2026, grants Owkin access to AstraZeneca’s proprietary “K Pro” artificial‑intelligence agents. The partnership is intended to accelerate decision‑making in drug discovery across AstraZeneca’s therapeutic areas, which include gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia and infection.
In the same week, AstraZeneca reported significant clinical results for its hypoparathyroidism candidate, eneboparatide (AZP‑3601). Phase III data from the Calypso study reached the primary endpoint, confirming the drug’s efficacy in patients with hypoparathyroidism. The company publicly hailed the outcome as encouraging and indicated that the results support continued development toward regulatory submission.
On 12 May 2026, AstraZeneca’s AZD5904 entered the PCT patent protection stage, expanding its intellectual‑property portfolio. The same day, the company’s stock fell after a U.S. FDA advisory panel rejected the new cancer drug’s application, reflecting regulatory uncertainty.
Market data for the week ending 11 May 2026 show a close price of 13 748 GBX, with a 52‑week high of 15 732 GBX (17 February 2026) and a 52‑week low of 9 932 GBX (14 May 2025). The market capitalization stands at 286 841 494 800 GBX, and the price‑earnings ratio is 27.55.
AstraZeneca remains listed on the London Stock Exchange, operating from its Cambridge headquarters and continuing its research, manufacturing and sales activities across eight therapeutic areas.
